Page 2 - Journal Of Comparative Effectiveness Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Journal of comparative effectiveness research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Journal Of Comparative Effectiveness Research Today - Breaking & Trending Today

Targeted Therapy Associated With Lower SPM Risk Among Treated Patients With CLL

Investigators found patients receiving chemotherapy had a greater risk of a secondary primary malignancy (SPM) compared with those treated with targeted therapies or those whose chronic lymphocytic leukemia (CLL) was left untreated. ....

Journal Of Comparative Effectiveness Research , Comparative Effectiveness , End Results , Secondary Primary Malignancy , Chronic Lymphocytic Leukemia , Targeted Therapies ,

Claims Data Suggest High Clinical, Economic Burden of MG Exacerbations Despite Treatment Options

The data suggest this burden among patients who have myasthenia gravis (MG) is prevalent across insurance types.
....

Journal Of Comparative Effectiveness Research , Comparative Effectiveness Research , Myasthenia Gravis , Economic Burden , Health Care Utilization , Medicare Coverage , Third Exacerbation ,

Adjuvant Therapy For Early-Stage NSCLC After Surgery Yields Lower Costs

Adjuvant therapy, instead of just surgery alone, for early-stage non-small-cell lung cancer (NSCLC) after surgery incurs lower medical costs than surgery alone. ....

United States , Journal Of Comparative Effectiveness Research , Comparative Effectiveness , Lung Cancer , Early Stage , Non Small Cell Lung Cancer ,

New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera

BURLINGTON, Mass., August 04, 2023 PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the publication of a cost-effectiveness analysis of ropeginterferon alfa-2b-njft (marketed as BESREMi®) in the Journal of Comparative Effectiveness Research. The analysis, titled "Cost-Effectiven ....

United States , South Korea , T Ai Pei , Raymond Urbanski , Pharmaessentia Tpex , Aaron Gerds , Ann Hematol , Pharmaessentia United States Corporation , Institute For Clinical , Pharmaessentia Corporation , Journal Of Comparative Effectiveness Research , Pharmaessentia Corporation Tpex , Affairs At Pharmaessentia , Us Head Of Clinical Development , Case Comprehensive Cancer Center , National Comprehensive Cancer Network , Bonafedem Health Care , European Medicines Agency , Comparative Effectiveness Research , Comparative Effectiveness , Polycythemia Vera , Medical Director , Senior Vice President , Clinical Development , Medical Affairs , Pharmaessentia United States ,

New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad

Analysis published in the Journal of Comparative Effectiveness Research shows ropeginterferon alfa-2b-njft provided a cost-effective benefit in quality-adjusted life years compared to a commonly used treatment pathwayBURLINGTON, Mass. (BUSINESS WIRE) PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia C. ....

South Korea , United States , T Ai Pei , Raymond Urbanski , Pharmaessentia Tpex , Aaron Gerds , Ann Hematol , Journal Of Comparative Effectiveness Research , National Comprehensive Cancer Network , Pharmaessentia United States Corporation , Bonafedem Health Care , Institute For Clinical , Pharmaessentia Corporation , European Medicines Agency , Us Head Of Clinical Development , Case Comprehensive Cancer Center , Pharmaessentia Corporation Tpex , Affairs At Pharmaessentia , Comparative Effectiveness Research , Comparative Effectiveness , Polycythemia Vera , Medical Director , Senior Vice President , Clinical Development , Medical Affairs , Pharmaessentia United States ,